Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer

• Published in: Antibodies (Basel) 2024-06, Vol.13 (2), p.46
• Main Authors: Chaudhry, Zuhair, Boyadzhyan, Anik, Sasaninia, Kayvan, Rai, Vikrant
• Format: Article
• Language: English
• Subjects: Antigen (tumor-associated); Antigen presentation; Barriers; Biomarkers; BRCA2 protein; Breast cancer; Cancer therapies; Cancer vaccines; Care and treatment; Cell cycle; Cell growth; Chemotherapy; Context; Diagnosis; Estrogens; Growth factors; Health aspects; Hormone replacement therapy; immune response; Immune system; Immunogenicity; Immunoglobulins; Immunotherapy; Kinases; Ligands; Literature reviews; Lymphocytes; Lymphocytes T; Medical prognosis; Metastasis; Mortality; Mutation; Neoantigens; Nucleotides; p53 Protein; Peptides; personalized therapy; Precision medicine; Protein-tyrosine-phosphatase; Proteins; Radiation therapy; Receptor mechanisms; Receptors; Review; Survivin; targeted therapy; Transcriptomics; Tumor antigens; Tumors; Tyrosine; Vaccines
• ISSN: 2073-4468; 2073-4468
• DOI: 10.3390/antib13020046

As one of the most prevalent forms of cancer worldwide, breast cancer has garnered significant attention within the clinical research setting. While traditional treatment employs a multidisciplinary approach including a variety of therapies such as chemotherapy, hormone therapy, and even surgery, researchers have since directed their attention to the budding role of neoantigens. Neoantigens are defined as tumor-specific antigens that result from a multitude of genetic alterations, the most prevalent of which is the single nucleotide variant. As a result of their foreign nature, neoantigens elicit immune responses upon presentation by Major Histocompatibility Complexes I and II followed by recognition by T cell receptors. Previously, researchers have been able to utilize these immunogenic properties and manufacture neoantigen-specific T-cells and neoantigen vaccines. Within the context of breast cancer, biomarkers such as tumor protein 53 (TP53), Survivin, Partner and Localizer of BRCA2 (PALB2), and protein tyrosine phosphatase receptor T (PTPRT) display exceeding potential to serve as neoantigens. However, despite their seemingly limitless potential, neoantigens must overcome various obstacles if they are to be fairly distributed to patients. For instance, a prolonged period between the identification of a neoantigen and the dispersal of treatment poses a serious risk within the context of breast cancer. Regardless of these current obstacles, it appears highly promising that future research into neoantigens will make an everlasting impact on the health outcomes within the realm of breast cancer. The purpose of this literature review is to comprehensively discuss the etiology of various forms of breast cancer and current treatment modalities followed by the significance of neoantigens in cancer therapeutics and their application to breast cancer. Further, we have discussed the limitations, future directions, and the role of transcriptomics in neoantigen identification and personalized medicine. The concepts discussed in the original and review articles were included in this review article.